Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.
The EMERALD-3 study evaluated the efficacy and safety of combining STRIDE (tremelimumab and durvalumab) with or without lenvatinib and transarterial chemoembolisation (TACE) in patients with embolisation-eligible…
Why it matters
This study provides evidence that combining immunotherapy with lenvatinib and TACE may improve progression-free survival in patients with embolisation-eligible HCC, potentially influencing treatment strategies in this…